Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II

被引：0
|
作者：
Arroyo Gonzalez, R. [1 ]
Moreau, T. [2 ]
Cohen, J. A. [3 ]
Giovannoni, G. [4 ]
Margolin, D. H. [5 ]
Kasten, L. [6 ]
Havrdova, E. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Burgundy Univ, Dijon Univ Hosp, Dijon, France
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Queen Mary Univ London, Barts & London Sch Med, London, England
[5] Genzyme, Cambridge, MA USA
[6] PROMETRIKA LLC, Cambridge, MA USA
[7] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2015年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
F2070
引用
收藏
页码：614 / 614
页数：1
相关论文
共 50 条
  • [21] Improvements in quality of life over 5 years with alemtuzumab are associated with confirmed disability improvement in patients with active relapsing-remitting multiple sclerosis who had an inadequate response to prior therapy (CARE-MS II)
    Arroyo Gonzalez, R.
    Dive, D.
    Dreyer, M.
    Hupperts, R. M. M.
    LaGanke, C.
    Lycke, J.
    Moreau, T.
    Singer, B.
    Margolin, D. H.
    Thangavelu, K.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 382 - 383
  • [22] Alemtuzumab improves clinical outcomes over 4 years in patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a: CARE-MS II extension study 4-year follow-up
    Boyko, A. N.
    Barnett, M.
    Brassat, D.
    Dive, D.
    Hupperts, R. M. M.
    Lycke, J.
    Montalban, X.
    Sharrack, B.
    Wray, S.
    Margolin, D. H.
    Thangavelu, K.
    Chirieac, M.
    Wiendl, H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 326 - 327
  • [23] Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study
    Soelberg-Sorensen, Per
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Twyman, Cary
    Lake, Stephen
    Margolin, David
    Richards, Susan
    Sung, Crystal
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [24] Alemtuzumab improves patient-reported quality of life in relapsing-remitting multiple sclerosis: CARE-MS I and II phase 3 trials
    Selmaj, K.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. P.
    Havrdova, E.
    Weiner, H.
    Brinar, V.
    Boscoe, A.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Rizzo, M.
    Compston, A.
    JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S66
  • [25] Alemtuzumab improves MRI outcomes in treatment-naive active relapsing-remitting multiple sclerosis patients: three-year follow-up from CARE-MS I
    Arnold, D. L.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Fisher, E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 41 - 41
  • [26] Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II
    Fernandez, O.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Twyman, C. L.
    Miller, T.
    Lake, L.
    Margolin, D. H.
    Panzara, M. A.
    JOURNAL OF NEUROLOGY, 2013, 260 : S14 - S14
  • [27] Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study
    Coles, A. J.
    Arnold, D. L.
    Cohen, J. A.
    Fox, E. J.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 107 - 108
  • [28] Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study
    Macdonell, R. A. L.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 806 - 806
  • [29] Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II)
    LaGanke, C.
    De Seze, J.
    Freedman, M. S.
    Habek, M.
    Hupperts, R. M. M.
    Limmroth, V.
    Macdonell, R. A. L.
    Selmaj, K. W.
    Margolin, D. H.
    Thangavelu, K.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 327 - 328
  • [30] Durable Suppression of Disease Activity by Alemtuzumab in the Absence of Continuous Treatment Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy (CARE-MS II)
    Macdonell, Richard A. L.
    LaGanke, Christopher
    De Seze, Jerome
    Freedman, Mark S.
    Habek, Mario
    Hupperts, Raymond M. M.
    Limmroth, Volker
    Selmaj, Krzysztof W.
    Margolin, David H.
    Thangavelu, Karthinathan
    Havrdova, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 339 - 339
12345